Synthesis and evaluation of daunorubicin-paclitaxel dimers

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 3, 2000, Pages 261-264

  Kar, Ari K ^a   Braun, Patrick D ^a   Wandless, Thomas J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DIMER; DNA; MICROTUBULE PROTEIN; PACLITAXEL;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; MAMMAL CELL; MICROTUBULE; NONHUMAN; PROTEIN DNA BINDING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; DAUNORUBICIN; DIMERIZATION; DRUG SCREENING ASSAYS, ANTITUMOR; PACLITAXEL; SPECTROMETRY, FLUORESCENCE; TUMOR CELLS, CULTURED;

ANIMALIA; MAMMALIA;

EID: 0034615062     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00667-8     Document Type: Article

References (22)

1. Mammen M., Choi S.K., Whitesides G.M. Angew. Chem., Intl. Ed. Engl. 37:1998;2755.
2. Glick G.D., Toogood P.L., Wiley D.C., Skehel J.J., Knowles J.R. J. Biol. Chem. 266:1991;23660.
3. Spaltenstein A., Whitesides G.M. J. Am. Chem. Soc. 113:1991;686.
4. Sabesan S., Duus J.O., Neira S., Domaille P., Kelm S., Paulson J.C., Bock K. J. Am. Chem. Soc. 114:1992;8363.
5. Lees W.J., Spaltenstein A., Kingery-Wood J.E., Whitesides G.M. J. Med. Chem. 37:1994;3419.
6. Mammen M., Dahmann G., Whitesides G.M. J. Med. Chem. 38:1995;4179.
7. Nicolaou K.C., Dai W.M., Guy R.K. Angew. Chem., Intl. Ed. Engl. 33:1994;15.
8. George G.I., Cheruvalath Z.S., Van der Velde D.G., Himes R.H. Tetrahedon Lett. 36:1995;1783.
9. Guy R.K., Scott Z.A., Sloboda R.D., Nicolaou K.C. Chem. Biol. 3:1996;1021.
10. Doxorubicin; Arcamone, F., Ed.; Academic Press: New York, 1981.
11. Wang A.H.-J., Ughetto G., Quigley G.J., Rich A. Biochemistry. 26:1987;1152.
12. Hu G.G., Shui X., Leng F., Priebe W., Chaires J.B., Williams L.D. Biochemistry. 36:1997;5940.
13. 13C); 5c: calcd 1582, found 1605 (M + Na); 5d: calcd 1582, found 1605 (M+Na); 5e: calcd 1562, found 1563 (MH+); 5f: calcd 1560, found 1583 (M+Na).
14. Chaires J.B., Dattagupta N., Crothers D.M. Biochemistry. 21:1987;1152.
15. 3H]PTX (5 μgCi/μmol, Moravek Biochemical) and other competing drugs were added to the solution containing the assembled MTs and incubated for an additional 45 min at 37 °C. The MTs were then pelleted by centrifugation at 14,000 rpm in an Eppendorf microfuge for 30 min. The supernatants were carefully removed and the pellets were resuspended in 0.1 M NaOH solution then neutralized with 0.1 M HCl and transferred to a scintillation vial. Approximately 5 mL of Cytoscint liquid scintillation cocktail was added to each, and the samples were counted on a Beckman LS 3801 Liquid Scintillation Counter.
16. UV-visible absorption spectra were measured for solutions of DNR (0-50 μM). Next, tubulin (1.0 mg/mL) was treated with varying amounts of DNR (0-50 μM) in either the presence or absence of PTX (10 μM). All protein containing samples were pelleted by centrifugation, and the supernatants were analyzed spectrophotometrically. The absorption at 480 nm for all solutions was plotted as a function of DNR concentration.
17. Mosmann T. J. Immunological Methods. 65:1983;55.
18. 50. Values reported for PTX + DNR combination are the concentrations of each compound for a total drug concentration twice the reported value.
19. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor I. Cancer Res. 51:1991;4226.
20. Ling Y.-H., Tornos C., Perez-Soler R. J. Biol. Chem. 273:1998;18984.
21. Blagosklonny M.V., Giannakakou P., El-Diery W.S., Kingston D.G.I., Higgs P.I., Neckers L., Fojo T. Cancer Res. 57:1997;130.
22. Nogales E., Whittaker M., Milligan R.A., Downing K.H. Cell. 96:1999;79.